Activ Surgical, a Boston-based startup founded in 2017, closed $11 million in Series A funding. Activ Surgical raised $13 million in July 2019 and $1.5 million in Seed funding in July 2017.
Activ Surgical is focused on improving surgical efficiency, accuracy, patient outcomes and accessibility for both endoscopic and robotically-assisted procedures. Activ Surgical is a resident of MassRobotics, a non-profit organization serving as the innovation hub for robotics and connected devices.
Activ Surgical’s scalable and patented surgical software platform, called ActivSight, is scheduled to launch in fall 2020. Driven by computer vision, AI, analytics and machine learning, ActivSight is designed to enhance a surgeon’s intra-operative decision making and reduce unintended and preventable surgical complications. The company says it can “provide real-time intra-operative visual data and images not currently available to surgeons through existing technologies.”
The Robot Report is launching the Healthcare Robotics Engineering Forum, which will be on Dec. 9-10 in Santa Clara, Calif. The conference and expo will focus on improving the design, development, and manufacture of next-generation healthcare robots. Learn more about the Healthcare Robotics Engineering Forum, and registration is now open.
The latest financing round, led by DNS Capital, will allow accelerate the commercialization of ActivSight. Other investors in the round included GreatPoint Ventures (GPV), Tao Capital Partners, SONY Innovation Fund, Rising Tide Financial, WS Investment Company and Mintz.
“The enthusiasm and level of support from a diverse group of investors validates our unique and proprietary technology,” said Todd Usen, Chief Executive Officer, Activ Surgical. “The funding will be used to continue to grow the organization and prepare for the 2020 launch of ActivSight, an advanced software and sensing platform that will provide clinicians around the world with intra-operative visual data and images not currently available through existing technologies.”
Activ Surgical’s technology spun out from the work of Dr. Peter Kim, a pediatric surgeon who supervised the first autonomous robotic suturing of soft tissue.
“Activ Surgical’s integration of advanced imaging technology and artificial intelligence positions the company to have an enormous impact on the future of healthcare by improving patient outcomes, reducing healthcare costs, and addressing unintended surgical complications,” said Michael Pucker, Chairman and CEO of DNS Capital. “We look forward to working closely with the experienced Activ Surgical team and the company’s other investors to support their long-term growth plans.”
Tell Us What You Think!